Source comparison
Melanotan-1 for Photoprotection: Dosing Comparison
Induction Phase (Clinical Trial Standard) 0.16mg/kg subcutaneous Every 48–72 hours for 10–14 days 10–14 days (visible pigment), 21–28 days (plateau) 30–45 days post-final dose Fastest pigmentation buildup; requires frequent dosing and strict adherence; standar
This comparison does not assign a generated winner or score.
- Induction Phase (Clinical Trial Standard)
- 0.16mg/kg subcutaneous
- Every 48–72 hours for 10–14 days
- 10–14 days (visible pigment), 21–28 days (plateau)
- 30–45 days post-final dose
- Fastest pigmentation buildup; requires frequent dosing and strict adherence; standard for research settings
- Maintenance Protocol (Extended Use)
- 0.08–0.12mg/kg subcutaneous
- Once every 7–10 days
- Assumes induction phase completed; maintains existing pigmentation
- Sustained as long as dosing continues
- Lower per-dose burden after induction; pigmentation fades within 30–60 days if discontinued
- Controlled-Release Implant (Afamelanotide)
- 16mg implant subcutaneous
- Once every 60 days
- 10–14 days (visible pigment), sustained release over 60 days
- 60–90 days per implant
- Eliminates frequent dosing; not available via compounding; used in clinical trials for EPP and PLE